浏览全部资源
扫码关注微信
- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
Research progress of anticoagulant drugs targeting coagulation factor Ⅺ
- ZHONGGUO YAOFANG Vol. 35, Issue 17, Pages: 2165-2170(2024)
- 作者机构：
1.天津市西青医院药剂科，天津 300380
2.天津医科大学朱宪彝纪念医院天津市内分泌研究所国家卫健委激素与发育重点实验室/天津市代谢性疾病重点实验室，天津 300134
- 作者简介：
- 基金信息：
DOI：10.6039/j.issn.1001-0408.2024.17.19
CLC： R973+.2Published：15 September 2024，
Received：04 February 2024，
Revised：22 August 2024，
- 稿件说明：
移动端阅览
苑新文,赵振宇.以凝血因子Ⅺ作为靶点的抗凝血药研究进展 Δ[J].中国药房,2024,35(17):2165-2170.
YUAN Xinwen,ZHAO Zhenyu.Research progress of anticoagulant drugs targeting coagulation factor Ⅺ[J].ZHONGGUO YAOFANG,2024,35(17):2165-2170.
苑新文,赵振宇.以凝血因子Ⅺ作为靶点的抗凝血药研究进展 Δ[J].中国药房,2024,35(17):2165-2170. DOI： 10.6039/j.issn.1001-0408.2024.17.19.
YUAN Xinwen,ZHAO Zhenyu.Research progress of anticoagulant drugs targeting coagulation factor Ⅺ[J].ZHONGGUO YAOFANG,2024,35(17):2165-2170. DOI： 10.6039/j.issn.1001-0408.2024.17.19.
摘要
抗凝血药是预防和治疗血栓栓塞性疾病的基石。现有的肠外和口服抗凝血药通过干扰凝血级联反应的关键环节，实现了对血栓的有效控制，但同时也伴随着出血风险的增加。以凝血因子Ⅺ（FⅪ）为靶点的抗凝血药——FⅪ抑制剂可通过抑制FⅪ来阻断凝血酶生成过程中的扩增阶段，减少血栓生成，且对正常止血作用的影响较小，已成为最有潜力的新型抗凝血药之一。目前尚无上市的FⅪ抑制剂类药物，而处于Ⅱ期或Ⅲ期临床试验阶段的FⅪ抑制剂包括3类——反义寡核苷酸、单克隆抗体和小分子抑制剂。另外，靶向FⅪ的天然抑制剂和核酸适配体大多正在进行临床前研发。作为抗凝治疗的新靶点药物，FⅪ抑制剂有望成为更安全、有效的治疗选择，弥补当前抗凝血药的局限性，在减少出血风险的同时为患者提供更有效的血栓预防和治疗方案。
Abstract
Anticoagulants are the cornerstone of the prevention and treatment of thromboembolic diseases. Existing parenteral and oral anticoagulants achieve effective control of thrombosis by interfering with key aspects of the coagulation cascade reaction， but this is accompanied by an increased risk of bleeding. FⅪ inhibitors， anticoagulants targeting coagulation factor Ⅺ （FⅪ）， can block the amplification phase of the thrombin generation process by inhibiting FⅪ， reducing thrombogenesis with less impact on normal hemostatic effects， and have become one of the most promising new anticoagulants. There are currently no marketed FⅪ inhibitor drugs， while FⅪ inhibitors in phase Ⅱ or phase Ⅲ clinical trials include 3 classes：antisense oligonucleotide， monoclonal antibody and small molecule inhibitors. In addition， most of the natural inhibitors and nucleic acid aptamers targeting FⅪ are under preclinical development. As new target drugs for anticoagulation therapy， FⅪ inhibitors are expected to become a safer and more effective therapeutic option， compensating for the limitations of current anticoagulants and providing patients with more effective thromboprophylaxis and therapeutic options while reducing the risk of bleeding.
关键词
抗凝血药凝血因子Ⅺ血栓形成FⅪ抑制剂血栓栓塞性疾病
Keywords
coagulation factor ⅪthrombosisFⅪ inhibitorsthromboembolic disease
references
《中国血栓性疾病防治指南》专家委员会. 中国血栓性疾病防治指南[J]. 中华医学杂志，2018，98（36）：2861-2888.
Expert Committee on the Guidelines for Prevention and Treatment of Thrombotic Diseases in China. Guidelines for prevention and treatment of thrombotic diseases in China[J]. Natl Med J China，2018，98（36）：2861-2888.
WEITZ J I，FREDENBURGH J C. 2017 scientific sessions Sol Sherry distinguished lecture in thrombosis：factor Ⅺ as a target for new anticoagulants[J]. Arterioscler Thromb Vasc Biol，2018，38（2）：304-310.
MEIJERS J C，TEKELENBURG W L，BOUMA B N，et al. High levels of coagulation factor Ⅺ as a risk factor for venous thrombosis[J]. N Engl J Med，2000，342（10）：696-701.
GROVER S P，MACKMAN N. Intrinsic pathway of coagulation and thrombosis[J]. Arterioscler Thromb Vasc Biol，2019，39（3）：331-338.
FREDENBURGH J C，WEITZ I J. Factor Ⅺ as a target for new anticoagulants[J].Hamostaseologie，2021，41（2）：104-110.
DE CATERINA R，PRISCO D，EIKELBOOM J W. Factor Ⅺ inhibitors：cardiovascular perspectives[J]. Eur Heart J，2023，44（4）：280-292.
SZÉKELY O，BORGI M，LIP G Y H. Factor Ⅺ inhibition fulfilling the optimal expectations for ideal anticoagulation[J]. Expert Opin Emerg Drugs，2019，24（1）：55-61.
BÜLLER H R，BETHUNE C，BHANOT S，et al. Factor Ⅺ antisense oligonucleotide for prevention of venous thrombosis[J]. N Engl J Med，2015，372（3）：232-240.
WALSH M，BETHUNE C，SMYTH A，et al. Phase 2 study of the factor Ⅺ antisense inhibitor IONIS-FⅪRx in patients with ESRD[J]. Kidney Int Rep，2021，7（2）：200-209.
ZHANG H，LÖWENBERG E C，CROSBY J R，et al. Inhibition of the intrinsic coagulation pathway factor Ⅺ by antisense oligonucleotides：a novel antithrombotic strategy with lowered bleeding risk[J]. Blood，2010，116（22）：4684-4692.
Ionis Pharmaceuticals Inc. Ionis announces positive topline results from phase 2b clinical study of fesomersen，a potential novel anti-thrombotic treatment[EB/OL]. （2022-07-28）[2024-08-10]. https：//www.prnewswire.com/news-releases/ionis-announces-positive-topline-results-from-phase-2b-clinical-study-of-fesomersen-a-potential-novel-anti-thrombotic-treatment-301594902.htmlhttps://www.prnewswire.com/news-releases/ionis-announces-positive-topline-results-from-phase-2b-clinical-study-of-fesomersen-a-potential-novel-anti-thrombotic-treatment-301594902.html.
YI B A，FREEDHOLM D，WIDENER N，et al. Pharmacokinetics and pharmacodynamics of Abelacimab （MAA868），a novel dual inhibitor of factor Ⅺ and factor Ⅺa[J]. J Thromb Haemost，2022，20（2）：307-315.
KOULAS I，SPYROPOULOS A C. A review of FⅪa inhibition as a novel target for anticoagulation[J]. Hamostaseo- logie，2023，43（1）：28-36.
WEITZ J I，BAUERSACHS R，BECKER B，et al. Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty：the FOXTROT randomized clinical trial[J]. JAMA，2020，323（2）：130-139.
LORENTZ C U，VERBOUT N G，WALLISCH M，et al. Contact activation inhibitor and factor Ⅺ antibody，AB023，produces safe，dose-dependent anticoagulation in a phase 1 first-in-human trial[J]. Arterioscler Thromb Vasc Biol，2019，39（4）：799-809.
PERERA V，WANG Z Q，LUETTGEN J，et al. First-in-human study of milvexian，an oral，direct，small molecule factor Ⅺa inhibitor[J]. Clin Transl Sci，2022，15（2）：330-342.
RAO S V，KIRSCH B，BHATT D L，et al. A multicenter，phase 2，randomized，placebo-controlled，double-blind，parallel-group，dose-finding trial of the oral factor Ⅺa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction[J]. Circulation，2022，146（16）：1196-1206.
SHOAMANESH A，MUNDL H，SMITH E E，et al. Factor Ⅺa inhibition with asundexian after acute non-cardio- embolic ischaemic stroke（PACIFIC-STROKE）：an international，randomised，double-blind，placebo-controlled，phase 2b trial[J]. Lancet，2022，400（10357）：997-1007.
PICCINI J P，CASO V，CONNOLLY S J，et al. Safety of the oral factor Ⅺa inhibitor asundexian compared with apixaban in patients with atrial fibrillation （PACIFIC-AF）：a multicentre，randomised，double-blind，double-dummy，dose-finding phase 2 study[J]. Lancet，2022，399（10333）：1383-1390.
BEALE D，DENNISON J，BOYCE M，et al. ONO-7684，a novel oral FⅪa inhibitor：safety，tolerability，pharmacokinetics and pharmacodynamics in a first-in-human study[J]. Br J Clin Pharmacol，2021，87（8）：3177-3189.
MA T T，DONG Y L，HUANG L，et al. SHR2285，the first selectively oral FⅪa inhibitor in China：safety，tole- rability，pharmacokinetics and pharmacodynamics combined with aspirin，clopidogrel or ticagrelor[J]. Front Pharmacol，2022，13：1027627.
JrPOLLACK C V，KURZ M A，HAYWARD N J. EP-7041，a factor Ⅺa inhibitor as a potential antithrombotic strategy in extracorporeal membrane oxygenation：a brief report[J]. Crit Care Explor，2020，2（9）：e0196.
PERERA V，LUETTGEN J M，WANG Z Q，et al. First-in-human study to assess the safety，pharmacokinetics and pharmacodynamics of BMS-962212，a direct，reversible，small molecule factor Ⅺa inhibitor in non-Japanese and Japanese healthy subjects[J]. Br J Clin Pharmacol，2018，84（5）：876-887.
CHEN W，CARVALHO L P，CHAN M Y，et al. Fasxiator，a novel factor Ⅺa inhibitor from snake venom，and its site-specific mutagenesis to improve potency and selecti- vity[J]. J Thromb Haemost，2015，13（2）：248-261.
PIREAUX V，TASSIGNON J，DEMOULIN S，et al. Anticoagulation with an inhibitor of factors Ⅺa and Ⅻa du- ring cardiopulmonary bypass[J]. J Am Coll Cardiol，2019，74（17）：2178-2189.
DONKOR D A，BHAKTA V，ELTRINGHAM-SMITH L J，et al. Selection and characterization of a DNA aptamer inhibiting coagulation factor Ⅺa[J]. Sci Rep，2017，7（1）：2102.
WOODRUFF R S，IVANOV I，VERHAMME I M，et al. Generation and characterization of aptamers targeting factor Ⅺa[J]. Thromb Res，2017，156：134-141.
0
Views
0
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
- Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号
公网安备50010302001817 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.